Esters of bendamustine are by far more potent cytotoxic agents than the parent compound against human sarcoma and carcinoma cells by Huber, Stefan et al.
RESEARCH ARTICLE
Esters of Bendamustine Are by Far More
Potent Cytotoxic Agents than the Parent
Compound against Human Sarcoma and
Carcinoma Cells
Stefan Huber1, Johannes Philip Huettner2, Kristina Hacker3, Günther Bernhardt1,
Jörg König3, Armin Buschauer1*
1 Pharmaceutical and Medicinal Chemistry II, Institute of Pharmacy, University of Regensburg, Regensburg,
Germany, 2 Pharmacology and Toxicology, Institute of Pharmacy, University of Regensburg, Regensburg,
Germany, 3 Institute of Experimental and Clinical Pharmacology and Toxicology, Friedrich-Alexander-
Universität Erlangen-Nürnberg, Erlangen, Germany
* armin.buschauer@chemie.uni-regensburg.de
Abstract
The alkylating agent bendamustine is approved for the treatment of hematopoietic malig-
nancies such as non-Hodgkin lymphoma, chronic lymphocytic leukemia and multiple mye-
loma. As preliminary data on recently disclosed bendamustine esters suggested increased
cytotoxicity, we investigated representative derivatives in more detail. Especially basic
esters, which are positively charged under physiological conditions, were in the crystal vio-
let and the MTT assay up to approximately 100 times more effective than bendamustine,
paralleled by a higher fraction of early apoptotic cancer cells and increased expression of
p53. Analytical studies performed with bendamustine and representative esters revealed
pronounced cellular accumulation of the derivatives compared to the parent compound. In
particular, the pyrrolidinoethyl ester showed a high enrichment in tumor cells and inhibition
of OCT1- and OCT3-mediated transport processes, suggesting organic cation transporters
to be involved. However, this hypothesis was not supported by the differential expression of
OCT1 (SLC22A1) and OCT3 (SLC22A3), comparing a panel of human cancer cells. Benda-
mustine esters proved to be considerably more potent cytotoxic agents than the parent
compound against a broad panel of human cancer cell types, including hematologic and
solid malignancies (e.g. malignant melanoma, colorectal carcinoma and lung cancer),
which are resistant to bendamustine. Interestingly, spontaneously immortalized human ker-
atinocytes, as a model of “normal” cells, were by far less sensitive than tumor cells against
the most potent bendamustine esters.
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Introduction
The alkylating agent bendamustine (1, Fig 1) was synthesized in 1963 [1, 2] and developed as
an anticancer drug in the German Democratic Republic [3–5]. In the 1990s bendamustine got
into the focus of research again [6]. It is approved for the treatment of chronic lymphocytic leu-
kemia (CLL) [7, 8], indolent non-Hodgkin lymphoma (NHL) [9] and multiple myeloma (MM)
[10, 11] or as second line therapy of refractory diseases [12–14] in various countries. Current
clinical trials suggest beneficial effects in the treatment of solid cancer types such as breast can-
cer [15] or small-cell lung cancer [16]. Most treatment regimens include bendamustine in com-
bination with other anticancer drugs including biologicals [17–20], for instance rituximab [17,
19, 20]. It has been hypothesized that, apart from the alkylating nitrogen mustard group
(N-Lost), the benzimidazole scaffold may contribute to the antitumor activity for instance, due
to antimetabolite properties, by facilitating nuclear transport or inhibiting DNA repair [6].
Besides the alkylation of DNA, causing strand breaks, bendamustine induces the expression of
p53 [21], triggers apoptosis [22] and down-regulates mitotic checkpoints, leading to mitotic
catastrophe [23, 24]. Recent patent applications aimed at formulations for oral administration
[25–27]. Alkyl (C1 –C24) esters of bendamustine were reported as potential prodrugs for intra-
venous application [28], and biodegradable polyphosphoesters were described as an approach
to stabilize bendamustine in solution [29]. Another approach aimed at increasing the cytotox-
icity by constructing dimeric and dendrimeric bendamustine derivatives [30].
Exploring the properties of derivatives of bendamustine (1), esters of bendamustine (2–7,
Fig 1) [31] comprising basic moieties (4–7) were prepared as potential prodrugs with higher
solubility compared to simple esters such as compounds 2 and 3, which were mainly prepared
as synthetic intermediates [32, 33]. Very recently, we reported on the stability of the nitrogen
mustard and the ester moieties in compounds 2–7 against hydrolysis and enzymatic cleavage
in buffer, in the presence of porcine butyrylcholine esterase as well as in human and murine
plasma [34]. The moderately basic morpholinoethyl ester (4) proved to be of particular interest
with respect to both solubility and stability [34]. Preliminary data suggested considerably
increased cytotoxicity of the esters compared to the parent compound 1, the basic compounds
being of particular interest [31]. Based on the assumption that higher antiproliferative activity
may result from increased cellular accumulation, additional mechanisms of action or both, we
compared compounds 2–7 with bendamustine (1) regarding cytotoxicity against a panel of
Fig 1. Structures of bendamustine (1) and the bendamustine esters 2–7.
doi:10.1371/journal.pone.0133743.g001
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human cancer cell types, representing hematologic and solid malignancies. Additionally, the
induction of p53 expression and apoptosis, cellular enrichment and the involvement of the
organic cation transporters OCT1 and OCT3 were investigated.
Materials and Methods
Ethics Statement
Human embryonal kidney (HEK293) cells were purchased from the German Collection of
Microorganism and Cell Cultures (DSMZ, Braunschweig, Germany). Cancer cell lines were
obtained from the American Type Culture Collection (ATCC; Rockville, MD, USA): SK-MEL-
3 (malignant melanoma; HTB-69), Capan-1 (pancreatic adenocarcinoma; HTB-79), HT-29
(colorectal adenocarcinoma; HTB-38), SK-ES-1 (Ewing´s sarcoma; HTB-86), HEL92.1.7 (ery-
throleukemia; TIB-180), Jurkat (acute T-cell leukemia; TIB-152), U-937 (histiocytic lym-
phoma; CRL-1593.2), LNCaP (prostate cancer; CRL-1740) and NCI-H460 (large cell lung
cancer; HTB-177), and MG-63 (osteosarcoma; CRL-1427) cells. HaCaT human skin keratino-
cyte cells (cryovial, 300493) were from Cell Line Service (CLS, Eppelheim, Germany).
Chemicals and Reagents
Bendamustine hydrochloride (1) and the esters 2–7 were kindly provided by Arevipharma
(Radebeul, Germany). Stock and working solutions of 1–7 were prepared in dimethylsulfoxide
(DMSO). Thiazolyl blue tetrazolium bromide (MTT), umbelliferone, 4-[4-(dimethylamino)
styryl]-N-methylpyridinium iodide (ASP+), penicillin-streptomycin and tetrapentyl ammo-
nium (TPA) were from Sigma (Taufkirchen, Germany). Hygromycin B was from A.G. Scien-
tific, (San Diego, CA, USA). Fetal calf serum (FCS) was from Biochrom (Berlin, Germany). A 1
mM stock solution of TPA was prepared in phosphate buffered saline (PBS). The 100 μM stock
solution of ASP+ was prepared in PBS containing 10% DMSO. HPLC-grade acetonitrile was
from Fisher Scientific (Schwerte, Germany). Demineralized water was prepared with a Milli-Q
system (Merck; Schwalbach, Germany). If not otherwise stated, all other reagents were of ana-
lytical grade and purchased from Sigma (Taufkirchen, Germany).
Cell Culture
Cancer and HaCaT cells. All media were from Sigma (Taufkirchen, Germany) and supple-
mented with 10% FCS. SK-MEL-3, Capan-1, HT-29 and SK-ES-1 cells were cultured in McCoy
´s 5A medium, supplemented with 2.2 g/L NaHCO3 (Merck, Darmstadt, Germany). HEL92.1.7,
Jurkat, U-937, LNCaP and NCI-H460 were cultured in RPMI-1640 containing 110 mg/L sodium
pyruvate, 10 mMHEPES (both from Serva, Heidelberg, Germany) and 2.0 g/L NaHCO3. MG-
63 cells were cultured in EMEM supplemented with 2.2 g/L NaHCO3. HaCaT cells were cultured
in RPMI-1640, containing 110 mg/l sodium pyruvate, 10 mMHEPES, 2.0 g/l NaHCO3 and
additional 2.5 g/L D-glucose. All cell types were passaged following treatment with a solution
containing 0.05% trypsin and 0.025% EDTA. In case of human keratinocytes (HaCaT cells) cells
were pre-incubated with 0.05% EDTA for 10 min at 37°C before trypsination.
Genetically modified HEK293 cells. Transfected human embryonic kidney cells
(HEK293) were cultured in EMEM, supplemented with penicillin/streptomycin (100 U/mL /
100 μg/mL) and 250 μg/mL hygromycin B. The cells were cultured in a water-saturated atmo-
sphere with 5% CO2 at 37°C and passaged once to twice a week. Adherently growing cells were
treated with trypsin/EDTA (0.5 mg/mL / 0.22 mg/mL) (PAA, Pasching, Austria) and washed
with medium prior to transfer into new culture flasks. Cells growing in suspension were pas-
saged after mechanical separation of cell agglomerates.
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HEK293 cells expressing the human organic cation transporters OCT1 or OCT3.
Parental HEK293 cells were transfected with the plasmid pcDNA3.1/Hygro(-)-OCT1, contain-
ing the full length SLC22A1 cDNA (NM_003057) encoding the human OCT1 protein, as
described [35]. After hygromycin selection, single colonies were characterized for SLC22A1
mRNA expression by real-time qRT-PCR, and the cell clone with the highest expression was
further analyzed with respect to protein expression and [3H]-1-methyl-4-phenylpyridinium
([3H]MPP+) uptake (cf. Supporting Information). HEK-Co cells (control) were established by
the same method using the empty plasmid pcDNA3.1/Hy(-) for transfection [36] (characteri-
zation of HEK-OCT1 and HEK-Co cells cf. S1 Methods; S1 Fig). HEK-OCT3 cells were
recently described [37].
Chemosensitivity Assays
Depending on the characteristics of the cells, two different assays were performed. For adher-
ently growing cells (HaCaT, HT-29, NCI-H460, SK-MEL-3, MG-63, Capan-1), cytotoxic and
cytocidal effects were determined in the crystal violet assay [38], whereas for loosely adherent
cells (LNCaP, SK-ES-1) and cells growing in suspension (HEL 92.1.7, Jurkat, U-937) the MTT-
assay [39] was used with minor modifications [38]. In brief, 1.5  103 (HaCaT, HT-29,
NCI-H460, SK-MEL-3, MG-63, Capan-1) or 5  103 (Jurkat, U-937, HEL92.1.7, LNCaP,
SK-ES-1) cells per well were seeded into flat-bottom 96-well plates (Sarstedt, Nümbrecht, Ger-
many). All compounds were used as solutions prepared in DMSO and tested at final concentra-
tions (8 replicates per concentration) of 1, 3, 10, 30 and 50 μM. In case of the vehicle control
and and test compounds, the final DMSO concentration amounted to 0.1%. Absorbance was
measured at 580 nm in a 96-well plate reader (GENios pro microplate reader, Tecan, Salzburg,
Austria). Effects were quantified as previously described [40] for both assays.
In addition to long-term exposure, IC50 values were determined after an incubation period
of 96 hours, following the same procedure as described above (4 instead of 8 replicates). As sug-
gested by the National Cancer Institute [41] the corrected T/C values (T/Ccorr) were plotted
against the logarithm of the concentrations, and the IC50 values were calculated using Prism
5.01 (GraphPad Software, La Jolla, CA, USA) according to the “log (inhibitor) vs. normalized
response-variable slope” equation.
Detection of Apoptosis (Annexin V/Propidium Iodide Assay)
Apoptosis was determined by incubating proliferating Jurkat cells with medium containing 1,
2, 4 or 5 at a concentration of 10 μM or 0.1% of DMSO (untreated control). After different
periods of incubation (6, 24, 48 hours), samples were analyzed using the Annexin V-FITC apo-
ptosis detection kit l (BD Biosciences, Heidelberg, Germany) according to the manufacturer’s
protocol using 106 cells/mL. Cells were analyzed using a FACSCalibur flow cytometer (BD Bio-
sciences, Heidelberg, Germany). The compensation was performed for each experiment with
annexin V-FITC (530/30 BP filter) and propidium iodide (585/42 BP filter), respectively. At
least 1  104 events were registered per sample and debris as well as cell aggregates were
excluded by forward (FSC) versus side scatter (SSC) gates. Raw data were analyzed using
FlowJo V10 software (Treestar Inc., Ashland, OR, USA).
Detection of p53 Expression by Immunoblotting
The expression of the tumor suppressor p53 by NCI-H460 and HT-29 cells was determined
after incubating the cells with compounds 1, 2, 4 and 5 at different concentrations for 24
hours. The cells (from a 10-cm culture dish, 70% confluency) were washed twice with PBS and
harvested by scraping after addition of ice-cold buffer A (10 mMHEPES pH = 7.9, 10 mM
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KCl, 0.1 mM EDTA, 0.1 mM EGTA, protease inhibitor mix (Sigma-Aldrich)). After adding
Nonidet P-40 (NP-40) (Sigma, Taufkirchen, Germany) to a final concentration of 1%, the cell
suspensions were vortexed and subsequently centrifuged at 13000 g and 4°C for 30 seconds.
The pellets were re-suspended in buffer B (buffer A + 400 mMNaCl, 1% NP-40) and gently
agitated using a Sarmix M2000 (Sarstedt, Nümbrecht, Germany) at 4°C for 15 min, followed
by centrifugation (13000 g, 4°C, 5 min; Microfuge; Eppendorf, Hamburg, Germany). The con-
centration of soluble protein was determined according to Bradford using the Bio-Rad Protein
Assay (Bio-Rad Laboratories, Munich, Germany).
An amount of 30 μg total protein of each sample and 8 μL of a biotinylated molecular weight
standard (1:6 dilution) (Cell Signaling, Danvers, MA, USA) was separated by SDS-PAGE (12%
gel) and afterwards electroblotted (150 V, 30 min) to nitrocellulose membrane (Peqlab,
Erlangen, Germany). To prevent unspecific binding, the membranes were treated with milk
powder (5% (m/v) in buffer (150 mMNaCl, 20 mM Tris, 0.1% Tween 20, pH = 7.6)) before
incubation with anti-p53 rabbit mAb (dilution 1:1000) (Cell Signaling) and anti-histone H2B
Ab (dilution 1:1000) (Cell Signaling) as loading control at 4°C for 14 hours. The primary anti-
bodies and the “protein ladder” were simultaneously detected with a horseradish peroxidase
(HRP)-coupled donkey anti rabbit mAb (dilution 1:1000) (Santa Cruz biotechnology, Heidel-
berg, Germany) or the anti-biotin HRP-coupled antibody (dilution 1:5000) (Cell Signaling),
respectively. The incubation with the secondary antibody was performed at room temperature
for 1 hour. The bands were detected by bioluminescence using the Pierce ECLWestern Blot-
ting Substrate (Thermo Scientific, Dreieich, Germany). After exposure, the x-ray film (Amer-
sham Hyperfilm ECL, GE Healthcare, München, Germany) was developed (CAWOMAT 2000
IR, CAWO, Schrobenhausen, Germany) and analyzed using a GS-710 imaging densitometer
and Quantity One V. 4 software (Bio-Rad Laboratories, Munich, Germany).
Quantification of Cell-Associated Bendamustine and Derivatives
Accumulation of bendamustine and selected bendamustine esters by HT-29 and NCI-H460
cells was determined by HPLC. For this purpose, 1.5  106 cells/well were seeded into 6-well
plates (Sarstedt, Nümbrecht, Germany). After two days of cultivation, the cells were incubated
in PBS containing 30 μM of 1, 2, 4 or 5 and 200 μM of umbelliferone as internal standard at
37°C for 10 minutes. After removing the medium, the cells were washed three times with PBS.
Untreated cells were detached with trypsin/EDTA and counted. The treated cells were har-
vested by adding 200 μL of ice-cold perchloric acid (1 M) and scraping. Subsequently, the sam-
ples were vortexed and sonicated (Branson 3200 ultrasonic cleaner; Branson, Danbury, USA)
for 10 minutes. After 5 minutes of centrifugation (13000 g, 4°C), the supernatants were filtered
(0.2 μm Phenex; Phenomenex, Aschaffenburg, Germany) and directly analyzed by HPLC with
fluorescence detection according to a recently reported validated procedure [34]. The normali-
zation of the measured concentration to the cell count allowed for a calculation of the cell-asso-
ciated amount of the respective test compound. Additionally, the ratio of cell-associated
substance compared to the applied concentration (30 μM) was calculated based on an average
cell volume of 3 pL.
Flow Cytometric Determination of OCT1 and OCT3 Activity
The previously described fluorescent substrate of organic cation transporters, 4-(4-dimethyla-
minostyryl)-N-methylpyridinium (ASP+) [42–45], was used to determine the function of
OCT1 and OCT3 by flow cytometry in the absence and the presence of bendamustine and
selected bendamustine esters. HEK293 cells expressing the transporter of interest were trypsi-
nized and washed twice with PBS, prior to re-suspension of 0.5  106 cells in 500 μL of PBS
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containing 2% (v/v) FCS. The cells were incubated with ASP+ (100 μM stock solution in PBS
containing 10% DMSO) for 5 minutes, allowing for cellular accumulation, and subsequently
analyzed with a FACSCalibur flow cytometer. ASP+ was excited at 488 nm and the fluorescence
was measured using a 530/30 nm and a 585/42 band-pass filter. At least 1  104 single cells were
analyzed by appropriate FSC/SSC gating.
For the determination of Km, cell suspensions of HEK-OCT1 and HEK-OCT3 cells as well
as HEK-Co cells as control for unspecific uptake of ASP+ were incubated with ASP+ at increas-
ing concentrations at 37°C for 5 minutes. Subsequently, two volumes of an ice-cold 200 μM
solution of the standard inhibitor of OCT1 and OCT3, tetrapentyl ammonium (TPA) [46–48],
in PBS/FCS were added to one volume of cell suspension. The mixture was immediately ana-
lyzed. The mean fluorescence intensities (MFI) were calculated using FlowJo V10, and the dif-
ference between total (HEK-OCT1 or HEK-OCT3 cells) and unspecific (HEK-Co cells) uptake
was plotted as specific uptake against the concentration of ASP+. The linearity of ASP+ uptake
(1 μM) at 37°C was assessed between 30 seconds and 7 minutes (HEK-OCT1) or 9 minutes
(HEK-OCT3), respectively. Km was calculated according to the Michaelis-Menten equation
using GraphPad Prism 5.01.
The inhibition of ASP+ uptake was measured to determine the IC50 values of TPA and com-
pounds 1, 2, 4 and 5. The cells were pre-incubated with the respective test compound at differ-
ent concentrations at room temperature for 10 minutes. Afterwards, ASP+ was added to a final
concentration of 1 μM, and the samples were incubated at 37°C in the dark for 5 minutes. Sub-
sequently, the cells were washed, re-suspended in ice-cold PBS/FCS and stored on ice in the
dark until measurement.
The normalized mean fluorescence intensities of the OCT expressing cells, set to 100% in
the absence of an inhibitor, were calculated by subtracting the mean fluorescence intensity of
unspecific ASP+ uptake into HEK-Co control cells. The normalized fluorescence intensities in
the presence of an inhibitor were plotted against the logarithm of the concentrations of the test
compounds to calculate IC50 values. The “log (inhibitor) vs. normalized response-variable slope”
equation of GraphPad Prism 5.01 was used for this purpose.
Imaging of Cellular ASP+ Uptake by Confocal Laser Scanning
Microscopy
HEK-Co, HEK-OCT1 and HEK-OCT3 cells were seeded into 8-well μ-Slides (Ibidi, Munich,
Germany) (2  104 cells/well) and allowed to attach for 48 hours. Prior to the staining proce-
dure, the medium was replaced by PBS and the DNA probe Draq5 (5 μM) (Biostatus,
Shepshed, UK) was added to each well. To monitor the inhibition of ASP+ uptake, 200 μM of
TPA or 15 μM of compound 5, respectively, were added and incubated at 37°C for 5 minutes.
Subsequently, ASP+ was added to reach a concentration of 1 μM, and the cells were incubated
for 5 minutes in the dark. Imaging was performed with an Axiovert 200 M confocal microscope
coupled to a Zeiss LSM 510 scanning device (Carl Zeiss, Oberkochen, Germany) using a Plan-
Apochromat 63x/1.40 oil immersion objective. Draq5 was excited at 633 nm and fluorescence
was detected using a 650 nm long-pass filter, ASP+ was excited at 488 nm and detected using a
565/35 nm band-pass filter.
Determination of OCT1 and OCT3 Expression by Various Cancer Cells
The expression of SLC22A1 and SLC22A3mRNA in different cancer cell types was analyzed by
quantitative RT-PCR using the Roche LightCycler system. Total RNA was isolated using the
NucleoSpin RNA Purification Kit (Macherey-Nagel, Dueren, Germany) according to the manu-
facturer’s instructions. One μg of total RNA was reversely transcribed using the iScript Kit
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(Biorad, Munich, Germany) according to the manufacturer´s instructions. SLC22A1, SLC22A3
and β-actinmRNA levels were determined using the LightCycler System and the FastStart DNA
Master SYBR Green I Kit (both from Roche, Mannheim, Germany). The primer pair for the
amplification of the SLC22A1 cDNA fragment was oOCT1-RT.for (CTGCCTGGTGAATGCT
GAGC) and oOCT1-RT.rev (ACATCTCTCTCAGGTGCCCG), for the SLC22A3 cDNA fragment
oOCT3-RT.for (CAAGCAATATAGTGGCAGGGG) and oOCT3-RT.rev (CCTCAAAGGTGAGA
GCGGGA) and for the β-actin fragment oActin.for (TGACGGGGTCACCACACACTGTGTGCC
CATCTA) and oActin.rev (CTAGAAGCATTTGCGGTGGACGATGGAGGG). PCR was performed
according to the manufacturer´s instructions with 0.5 μM of the respective sense and antisense
primers, 4 mMMgCl2 and 1-fold FastStart DNAMaster SYBR green I mix in a total volume of
20 μL including 1 μL of the synthesized sscDNA. Cycling conditions were as follows: 10 min
denaturation at 94°C, followed by 45 cycles of 10 s denaturation at 94°C, 15 s primer annealing
at 64°C and 30 s of elongation at 72°C. The amount of β-actin, SLC22A1 and SLC22A3 cDNAs
were determined using a serial plasmid dilution (pOCT1.31; from 106 to 104 fg) as amplification
standard. The β-actin concentration, calculated in relation to the standard curve, was set to
100% and the respective SLC22A1 and SLC22A3mRNA values are given as a percentage of β-
actin amplification.
Results and Discussion
Cytotoxicity of Bendamustine and Derivatives
The cytotoxicity of compounds 1–7 against tumor cells was determined both as an end point
and kinetically. Additionally, the toxicity of 1, 2, 4 and 5 was determined in kinetic assays at
spontaneously immortalized human keratinocytes (HaCaT), [49], as a model for “normal”
cells. IC50 values of compounds 1–7 (Table 1 and S2 Fig) were calculated after 96 hours of incu-
bation and the cytotoxic drug effect was measured over a period of 5 days (Fig 2 and S3–S13
Figs). In case of the crystal violet assay, the kinetic approach allows the distinction between
cytotoxic, cytostatic and cytocidal drug effects [40].
Although 1 is approved for hematologic malignancies, the effects on representative tumor
entities were rather weak (Table 1, Fig 2 and Supporting Information S3–S5 Figs). The IC50 val-
ues were> 80 μM against HEL 92.1.7 (erythroleukemia) and U-937 (histiocytic lymphoma),
and 43 μM against Jurkat cells (acute T-cell leukemia, Fig 2A). By contrast, the Ewing´s sar-
coma cells SK-ES-1 showed a distinct response upon treatment with bendamustine (IC50 ~
10 μM; Table 1, Fig 2B), whereas the chemosensitivity of MG-63 osteosarcoma cells was
markedly lower (IC50 ~ 56 μM) with cytocidal drug effects at concentrations above 30 μM (S6
Fig). Surprisingly, with an IC50 value< 20 μMCapan-1 pancreatic cancer cells showed moder-
ate chemosensitivity. On the contrary, 1 was ineffective (SK-MEL-3 melanoma, HT-29 colorec-
tal carcinoma) or only very weakly active (LNCaP prostate cancer; NCI-H460 large cell lung
cancer) against the other carcinoma cell types (IC50 values 78 to> 100 μM).
In contrast to the parent compound bendamustine, the derivatives 2–7 exhibited consider-
ably higher potencies up to factors> 100 both, against the cancer cells investigated. With
respect to the cytotoxic effects, compounds 2–7 fall into two groups: the alkyl esters (2, 3) and
the mofetil ester 4 on one hand, and the basic heterocyclic esters 5–7 on the other hand. Com-
pared to bendamustine, compounds 2–4 showed a 10- to 30-fold increase in potency, and 5–7
were 60- to 120-fold more potent than 1.
Compounds 2–4: Among compounds 2–4, minor differences were observed at SK-ES-1
and NCI-H460 cells (Table 1) with a more pronounced effect of the alkyl esters 2 and 3 against
SK-ES-1 cells (IC50 values: 2 and 3: ~ 0.2 μM, 4: 0.9 μM). The increase in toxicity compared to
1 was most striking at HEL92.1.7, LNCaP, MG-63 and, in case of the alkyl esters 2 and 3, at
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SK-ES-1 cells. Comparable IC50 values of 2–4 were confirmed by the cytotoxic drug effects
over a period of 5 days (S3–S13 Figs).
Compounds 5–7: Except for the hematologic malignancies (HEL92.1.7, Jurkat, U-937),
SK-ES-1 and LNCaP cells, compounds 5–7 exhibited a distinct increase in cytotoxicity com-
pared to 2–4, showing IC50 values in low micro- to nanomolar range and cytocidal effects at
concentrations as low as 1–10 μM at all treated cancer cells. The antiproliferative activity of
compounds 5–7 was comparable both, in the end-point (cf. Table 1) and in the kinetic assays
over a period of 5 days (S3–S12 Figs). Remarkably, compared to 1, compounds 5–7 were up
to> 100 times more potent against tumor cells such as SK-MEL3, NCI-H460, HT-29 and
MG-63, which were refractory against treatment with bendamustine.
The results of the kinetic toxicity assays on HaCaT cells (Fig 2, S13 Fig) compared to the
IC50 values (Table 1) and the data from kinetic cytotoxicity assays on cancer cells (Fig 2 and
S3–S13 Figs) revealed a preferential toxicity against tumor cells, suggesting a more favorable
“therapeutic index”, in particular in case of the esters 4 and 5.
Data on the in vitro cytotoxicity of bendamustine are scarce. In the literature, for myeloma
cells IC50 values around 100 μM or even higher are reported [22, 23]. A very recent study on
several hematologic malignancies revealed IC50 values between approximately 10 μM and
250 μM. Especially mantle cell lymphoma, Burkitt’s lymphoma and T-cell acute lymphoblastic
leukemia derived cell lines were relatively sensitive to bendamustine treatment [50]. The IC50
value (approximately 50 μM) reported by Hiraoka et al. [50] for Jurkat cells is in good agree-
ment with our data. Published plasma levels of 1 after intravenous administration (Cmax =
6 μg/mL ( 17 μM) [51]; Cmax = 11 μg/mL ( 31 μM) [52]) suggest that the chemotherapy
with bendamustine must be considered ineffective in case of tumor entities showing IC50 values
in the two- to three-digit micromolar range in vitro. In this context the up to 100-fold antipro-
liferative activity of the bendamustine esters, in particular 5–7, suggest both, higher efficacy in
case of malignancies for which the parent compound is approved and a possible extension of
the scope of indications.
Table 1. Cytotoxicity of compounds 1–7 against selected human cancer cell lines of different origin. Subgroups, representing hematological malig-
nancies, sarcoma, carcinoma and malignant melanoma, are separated by horizontal lines. IC50 values (μM) after 96 hours of incubation.
Cell line Supporting information Compound
1 2 3 4 5 6 7
HEL 92.1.7 a S3 Fig 86.2 ± 2.6 2.5 ± 0.1 2.9 ± 0.2 2.4 ± 1.0 1.0 ± 0.01 1.3 ± 0.1 1.7 ± 0.1
Jurkat a S4 Fig 43.4 ± 4.8 3.1 ± 0.1 3.8 ± 0.04 3.2 ± 1.0 0.61 ± 0.02 0.83 ± 0.01 0.90 ± 0.03
U-937 a S5 Fig 83.4 ± 8.5 1.8 ± 0.1 1.9 ± 0.01 3.2 ± 0.96 0.83 ± 0.19 1.1 ± 0.2 1.3 ± 0.3
MG-63 b S6 Fig 55.8 ± 1.9 1.9 ± 0.1 2.1 ± 0.06 3.5 ± 0.1 0.38 ± 0.06 0.53 ± 0.01 0.55 ± 0.01
SK-ES-1 a S7 Fig 9.6 ± 0.3 0.18 ± 0.02 0.18 ± 0.01 0.91 ± 0.08 0.09 ± 0.01 0.19 ± 0.01 0.19 ± 0.03
Capan-1 b S8 Fig 18.9 ± 4.5 0.60 ± 0.04 1.0 ± 0.01 1.4 ± 0.01 0.12 ± 0.02 0.17 ± 0.01 0.25 ± 0.02
LNCaP a S9 Fig 77.9 ± 5.6 0.95 ± 0.15 1.5 ± 0.1 2.2 ± 0.1 0.50 ± 0.08 0.75 ± 0.03 0.93 ± 0.12
NCI-H460 b S10 Fig 90.0 ± 4.3 4.8 ± 0.3 4.8 ± 0.1 9.7 ± 1.3 0.90 ± 0.01 1.2 ± 0.1 1.2 ± 0.1
HT-29 b S11 Fig > 100 c 9.4 ± 0.4 10.0 ± 0.10 9.0 ± 0.5 1.1 ± 0.1 1.7 ± 0.1 2.4 ± 0.1
SK-MEL-3 b S12 Fig > 100 c 13.8 ± 0.4 21.7 ± 4.10 20.9 ± 0.9 0.83 ± 0.18 1.24 ± 0.1 1.0 ± 0.27
Data are mean values ± SEM of 3 independent assays with 4 replicates per compound concentration. For cytotoxicity data after long-term exposure (5
days) cf. Fig 2 and S3–S12 Figs as indicated.
a) MTT-assay
b) Crystal violet assay
c) Mean value ± SEM of 2 independent assays
doi:10.1371/journal.pone.0133743.t001
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Fig 2. Antiproliferative activity of compounds 1, 4 and 5 against selectedmalignant tumor cells and spontaneously immortalized human
keratinocytes upon long-term incubation. Jurkat (A; acute T cell leukemia), SK-ES-1 (B; Ewing’s sarcoma), NCI-H460 (C; large cell lung cancer) and HT-
29 (D; colorectal cancer) cells were treated with compounds 1, 4 and 5 at concentrations between 1 μM and 50 μM, HaCaT cells (E; spontaneously
immortalized human keratinocytes) were incubated with 1, 4 and 5 at 0.1, 1 and 10 μM. Incubation period: 5 days. Antiproliferative and cytotoxic effects
correspond to the left y-axes. The growth curves of untreated control cells (open circles) correspond to the right y-axes. Data are mean values ± SEM of at
least 2 independent assays with 8 replicates per compound concentration. For additional data on long-term cytotoxity of compounds 1–7 against various
tumor cell types and cytotoxicity of compound 2 against HaCaT cells cf. S3–S13 Figs.
doi:10.1371/journal.pone.0133743.g002
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Induction of Apoptosis and p53 Expression by Compounds 1, 2, 4 and 5
Bendamustine was reported to trigger apoptosis [22]. In search for an explanation of the higher
antiproliferative activity of the bendamustine esters compared to the parent compound, we
determined early and late stage of apoptosis by flow cytometry (annexin V/propidium iodide
staining) after treatment of Jurkat cells with 10 μM of compounds 1, 2, 4 or 5 for 6, 24 and 48
hours (Fig 3; S14 Fig). As becomes obvious from Fig 3, annexin V+/PI+cells, defined as second-
ary necrotic cells, amounted to approximately 10% of the total cell population, most probably
resulting from sample preparation. Only a fraction of approximately 1% of the cell population
was Annexin V-/PI+ and considered necrotic. As expected from the results of the MTT assay,
at a concentration of 10 μM, bendamustine had no effect compared to the control cells, regard-
less of the period of incubation. After 6 hours, the fraction of early apoptotic cells was less than
1% except for compound 5 (~2.5%; cf. Supporting Information, S14 Fig). Compounds 2 and 4
showed induction of apoptosis in around 10% of the cells after 24 hours of incubation. After 48
hours of incubation, 15% of the cells were in an early apoptotic state and a considerable frac-
tion (20–25%) was secondary necrotic. In agreement with the results from the chemosensitivity
assays, compound 5 was more potent, exhibiting a more rapid onset of action and a higher
maximal response compared to 1, 2 and 4 regarding induction of apoptosis. Approximately
50% of the cells were either early apoptotic (20%) or secondary necrotic (30%) after 24 hours.
Two days after treatment, only around 15% of the cells were viable, whereas the majority of the
cells was secondary necrotic (70%).
Bendamustine was reported to induce the expression of p53 [21, 23, 50]. As the derivatives
of 1 were much more potent against large cell lung and colorectal cancer cells, we investigated
the induction of p53 expression in NCI-H460 and HT-29 cells after 24 hours of incubation
with compounds 1, 2, 4 and 5 (Fig 4). Especially in NCI-H460 cells, p53 expression was signifi-
cantly induced by the treatment with 10 μM of compounds 2, 4 and 5, while 5 led to the most
pronounced effect. Bendamustine also weakly induced the expression of p53, although at a ten-
fold higher concentration (100 μM). Interestingly, p53 was only detectable in nuclear extracts
of NCI-H460 cells after treatment, whereas HT-29 cells exhibited a high constitutive expres-
sion of the tumor suppressor protein. Nevertheless, the treatment with compounds 1, 2, 4 and
5 increased the expression of p53 in HT-29 cells but, similar to NCI-H460 cells, compounds 2,
4 and 5 caused a higher expression level than 1. Another notable observation was a slight
induction of p53 expression in HT-29 cells after treatment with 10 μM of 1, since proliferation
assays revealed no toxic effect at this concentration. It is known from the literature that
Fig 3. Induction of apoptosis in Jurkat cells.Results of annexin V/propidium iodide staining, performed after incubating Jurkat cells with compounds 1, 2,
4 and 5 at a concentration of 10 μM for different periods. Annexin V+/PI- cells were defined as early apoptotic, whereas secondary apoptotic cells were
annexin V+/PI+. Significances illustrated on top of the columns refer to the overall effect (apoptotic + secondary necrotic cells), those depicted in the columns
refer to apoptotic cells. After 48 hours, apoptotic and secondary necrotic cells were significantly different (p < 0.001) (mean ± SEM, N = 3). One-way ANOVA
and Bonferroni’s post-test were applied to calculate the significance of the apoptotic fraction and the sum of apoptotic and secondary necrotic cells; n.s.: not
significant; *: p < 0.05; **: p < 0.01, ***: p < 0.001.
doi:10.1371/journal.pone.0133743.g003
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concentrations of 80 μM of bendamustine are required to produce a significant induction of
p53 expression in various tumor cell types [22]. Both, the induction of p53 and apoptosis, cor-
related with the cytotoxic potency of bendamustine and derivatives.
Cellular Accumulation of Bendamustine and Derivatives
Higher cellular uptake of the neutral (2, 3) and basic (4–7) bendamustine esters compared to
the parent compound could account for the increased potency in terms of antiproliferative
activity, induction of apoptosis and p53 expression. Therefore, we performed HPLC analyses
to determine the amount of cell-associated test compounds 1, 2, 4 and 5 at a concentration of
30 μM after 10 minutes of incubation. NCI-H460 and HT-29 cells were selected as examples of
solid tumors, which surprisingly proved to be sensitive against bendamustine esters (Fig 5).
Fig 4. Effect of 1, 2, 4 and 5 on the expression of p53 in NCI-H460 and HT-29 cells.Western blot of p53
and histone H2B (loading control) of NCI-H460 (A) and HT-29 (B) cells.A: Nuclear extracts of NCI-H460
cells, incubated with different concentrations of 1 (10, 30 and 100 μM) or 10 μM of 2, 4, or 5 for 24 hours.
Nuclear extracts (NE) and whole cell lysates (WCE) of untreated cells were used as control (Ctrl).B: Nuclear
extracts of HT-29 cells, incubated with 10 μM of 1, 2, 4, 5 for 24 hours. Untreated cells served as control (Ctrl).
doi:10.1371/journal.pone.0133743.g004
Fig 5. Accumulation of 1 and derivatives by HT-29 and NCI-H460 cells. Amount (mean ± SEM, N = 3–4)
of cell-associated 1, 2, 4 and 5, expressed as nmol/106 cells (left y-axis) and cellular enrichment (right y-axis)
in HT-29 (A) and NCI-H460 (B) cells. A mean cell volume of 3 pL was used to calculate accumulation factors.
Significance was calculated using one-way Anova: n.s.: not significant; *: p < 0.05; **: p < 0.01, ***:
p < 0.001.
doi:10.1371/journal.pone.0133743.g005
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The recently reported validated HPLC method was applied [34]. To prevent hydrolysis of
the nitrogen mustard group during sample preparation and analysis, cell lysis and deproteina-
tion were performed under acidic conditions (1 M perchloric acid, sonication). The esters were
proven to be stable over the incubation period of 10 minutes in the presence of cells (S15 Fig).
The cellular association of the internal standard umbelliferone did not significantly differ
between both cell lines (p> 0.05). The amounts of cell-associated bendamustine (1) were
extremely low (HT-29: 0.07 ± 0.011 nmol/106 cells; NCI-H460: 0.03 ± 0.001 nmol/106 cells).
The ratio of cell-associated to the applied concentration of the test compound (accumulation
factor) was 1:3 for NCI-H460 cells and 2:3 for HT-29 cells, indicating an incomplete uptake. In
contrast, compounds 2, 4 and 5 revealed considerably higher cell-associated amounts, with 5
reaching the highest cellular concentrations. A pronounced cellular enrichment of 2, 4 and 5
was particularly observed in HT-29 cells. Compounds 2 (2.05 ± 0.39 nmol/106 cells) and 4
(1.59 ± 0.23 nmol/106 cells) revealed a 20- to 30-fold, and 5 (5.01 ± 0.34 nmol/106 cells) an
approximately 70-fold higher cellular enrichment than bendamustine. Qualitatively, the cellu-
lar accumulation of the bendamustine derivatives was comparable in HT-29 and NCI-H460
cells, though at a lower level (factor of approximately three) in case of the latter. The amounts
of cell-associated 2, 4 and 5 were 0.28 ± 0.06 nmol/106 cells, 0.59 ± 0.04 nmol/106 cells and
1.89 ± 0.14 nmol/106 cells, respectively.
The levels of cellular enrichment correlate very well with the antiproliferative activities,
underlining a crucial role of the ester moiety depending on the chemical nature, covering a
neutral group (2) or substructures with different degree of basicity (4 and 5). In particular, the
contribution of the pyrrolidino group in 5, which is positively charged under assay conditions,
becomes obvious from the increased cellular accumulation which is paralleled by the antiproli-
ferative activity, the induction of apoptosis and p53 expression. The high cellular accumulation
of 5 and the comparable effects of 5–7 concerning the toxicity suggest an important role of the
basic substituent and the positive charge for the cellular association and thus for the toxicity.
Apart from that, the significant difference between HT-29 and NCI-H460 cells might result
from a different extent of diffusion and transporter-mediated uptake. Therefore, a possible
contribution of organic cation transporters (OCT) was taken into account [53]. To test this
hypothesis, functional studies on recombinant OCT1 and OCT3, expressed in HEK293 cells,
were performed. Additionally, the expression of the respective transporters by the tumor cell
types selected for cytotoxicity studies was investigated.
Effect of Bendamustine Derivatives on the Activities of OCT1 and OCT3
ASP+ uptake by OCT1 and OCT3 expressing HEK293 cells
Confocal laser scanning microscopy revealed specific uptake of the fluorescent substrate ASP+
by organic cation transporter expressing HEK293 cells (Fig 6). OCT1 activity was lower than
that of OCT3. The activities of both transporters were inhibited by compound 5 and the refer-
ence inhibitor TPA (Fig 6).
Determination of the affinities of OCT1 and OCT3 to ASP+ as substrate. Flow cytome-
try was applied to determine Km values (Fig 7). The kinetics of ASP
+-uptake and thus the
increase in fluorescence were linear for both transporters (Fig 7A), allowing the determination
of initial velocities (v0) at different concentrations (Fig 7B). The affinity to ASP
+ was not signifi-
cantly different for OCT1 (Km = 3.1 ± 0.1 μM) and OCT3 (Km = 2.7 ± 0.1 μM). By contrast, the
maximal uptake rate for ASP+ was significantly higher for OCT3 [vmax = 5321 ± 89 MFI/(10
4
cells min)] than for OCT1 [vmax = 2808 ± 78MFI/(104 cells min)] (p< 0.001).
Inhibition of OCT mediated ASP+ uptake by bendamustine derivatives. Bendamustine
(1), the derivatives 2, 4 and 5 and the standard inhibitor tetrapentyl ammonium (TPA) were
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investigated in the flow cytometric ASP+-uptake assay to determine IC50 values. The IC50 values
of TPA in HEK-OCT1 (IC50 = 6.04 ± 0.83 μM) and HEK-OCT3 (IC50 = 19.9 ± 2.23) cells were
consistent with previously published data, obtained in a microtiter assay (OCT1: IC50 = 7.9 μM
[46], OCT3: IC50 = 28 μM [47]). Whereas compounds 2, 4 and 5 (Fig 8) revealed concentration-
dependent inhibition of both transporters, incomplete inhibition of OCT1 (35%) and OCT3
(37%) was observed at the highest examined concentration of bendamustine (200 μM). Com-
pounds 2 and 4 were comparable to TPA at OCT1, whereas 5 was more potent by a factor of
approximately 20 (Table 2). By contrast, compounds 2, 4 and 5 were almost equipotent at OCT3
and approximately four times more potent than the reference compound TPA (p 0.05). Sev-
eral studies conducted in the last years focused on the uptake of cytostatic drugs by organic cat-
ion transporters. Oxaliplatin [54], picoplatin [55], imatinib [56], paclitaxel and irinotecan [57]
were identified as OCT1 substrates and oxaliplatin [58], melphalan, irinotecan and vincristine
[59] as substrates for OCT3. Compared to other cytostatic drugs such as cisplatin (IC50
value> 100 μM at OCT1 [60]) and mitoxantrone (IC50 16 μM at OCT1; 440 μM at OCT3 [61]),
especially 5 revealed remarkably higher potency at OCT1 (IC50 0.35 ± 0.03 μM). Whether com-
pounds 2, 4 and 5 are inhibitors or substrates of OCT1 and OCT3 is a matter of question. Sup-
posed that these bendamustine derivatives, in particular the basic ester 5, are substrates,
accumulation and cytotoxicity should be related to the OCT expression.
Expression of OCT1 (SLC22A1) and OCT3 (SLC22A3) by cancer cells. Previously,
OCT1-mediated uptake of cytostatics in tumor cells was reported for chronic myeloid leukemia
[56], chronic lymphocytic leukemia [57], and colon carcinoma [54], whereas OCT3 expression
was associated with colorectal [58] and renal cancer [59]. We applied RT-PCR for the
Fig 6. Confocal laser scanningmicroscopy of cellular ASP+ uptake via OCT1 and OCT3.Uptake of
fluorescent ASP+ [1 μM] (green) in the absence and presence of compound 5 or TPA after 5 minutes of pre-
incubation. Nuclei were stained with Draq5 [5 μM] (red). A, B: HEK-Co (control) cells, treated with Draq5 (A) or
ASP+ plus Draq5 (B). C-E: HEK-OCT1 cells, treated with ASP+ plus Draq5 (C), ASP plus Draq5 plus
compound 5 [15 μM] (D), or ASP+ plus Draq5 plus TPA [200 μM] (E). F-H: HEK-OCT3 cells, treated with ASP+
plus Draq5 (F), ASP+ plus Draq5 plus compound 5 [15 μM] (G), or ASP+ plus Draq5 plus TPA [200 μM] (H).
doi:10.1371/journal.pone.0133743.g006
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examination of OCT1 and OCT3 expression in all used cancer cell lines (Fig 9, S16 Fig).
Whereas OCT1 was weakly expressed in SK-ES1 and SK-MEL3 cells (in both cell lines below
0.3%, related to β-actin expression) OCT3 expression was high in HT-29 cells (0.52%, propor-
tional to β-actin expression), and clear bands were detectable upon analysis of Capan-1 (0.05%,
proportional to β-actin expression) and LNCaP cells (0.14%, proportional to β-actin expres-
sion). The differential expression (Fig 9, S16 Fig) does not support the hypothesis that the che-
mosensivities of the investigated cancer cell types (Table 1) are primarily determined by OCT-
mediated uptake of the bendamustine esters.
Conclusion
Although the investigated compounds are sufficiently stable to act as antitumor agents on their
own, it cannot be precluded that the esters are only prodrugs, allowing for increased intracellu-
lar accumulation of bendamustine. Having the N-Lost moiety in common, alkylating property
is a characteristic feature of both, the parent compound and the derivatives. In concert with the
Fig 7. Specific uptake of ASP+ and Michaelis-Menten kinetics determined by flow cytometry. A: Time
dependency of the specific mean fluorescence intensity (MFI) after incubating HEK-OCT1 and HEK-OCT3
cells with 1 μMASP+ (means ± SEM, N = 3). B: Concentration dependency of the initial velocity of the specific
increase in the mean fluorescence intensity (MFI) caused by ASP+-uptake into HEK-OCT1 and HEK-OCT3
cells. HEK cells transfected with an empty vector served as control for unspecific uptake (means ± SEM,
N = 3).
doi:10.1371/journal.pone.0133743.g007
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Fig 8. Concentration-dependent inhibition of ASP+-uptake by OCT expressing HEK-cells. Inhibition of ASP+-uptake (1 μM) into HEK-OCT1 (A) and
HEK-OCT3 (B) cells by TPA, 2, 4 or 5. The mean fluorescence intensities were normalized to uninhibited ASP+-uptake (N = 3).
doi:10.1371/journal.pone.0133743.g008
Table 2. Inhibition of ASP+-uptake into HEK-OCT1 and HEK-OCT3 cells. IC50 (μM) values ± SEM
(N = 3).
Compound OCT1 OCT3
TPA 6.0 ± 0.8 19.9 ± 2.2
1 > 200 > 200
2 11.3 ± 1.9 5.1 ± 1.4
4 10.1 ± 2.5 5.1 ± 0.02
5 0.35 ± 0.03 3.41 ± 0.16
doi:10.1371/journal.pone.0133743.t002
Fig 9. Expression of OCT1 and OCT3 by various cancer cells.Gel electrophoretic analysis of SLC22A1 (encoding human OCT1) and SLC22A3
(encoding human OCT3) mRNA expression by different human cancer cell types after RT-PCR. Human SLC22A1mRNA was detected using the primer pair
oOCT1-RT.for–oOCT1-RT.rev, resulting in a specific band of 319 bp, human SLC22A3mRNA by the primer pair oOCT3-RT.for–oOCT3-RT.rev, resulting in
a band of 439 bp. As a positive control, the plasmids pOCT1.31 and pOCT3.31 (cDNA) were used as templates of SLC22A1 and SLC22A3, respectively.
NTC = non-template control.
doi:10.1371/journal.pone.0133743.g009
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increase in apoptotic processes and elevated p53 expression, the data may be interpreted as a
hint to a dual mechanism of action, in particular in case of the basic bendamustine esters.
Supporting Information
S1 Fig. Characterization of HEK293 cells stably expressing human OCT1. A: Immunoblot
analysis of lysates (20 μg each) of HEK-Co and HEK-OCT1 cells. OCT1 was detected with the
antiserum KEN (see: Material and Methods). B: Immunolocalization of human OCT1 in
HEK-Co and HEK-OCT1 cells by confocal microscopy. The OCT1 protein was detected in the
plasma membrane of transfected HEK-OCT1 cells and no OCT1-specific staining was detectable
in HEK-Co cells. C: Concentration dependent [3H]MPP+ uptake in HEK-Co and HEK-OCT1
cells (incubation time: 3 min). D: Time-dependent uptake of [3H]MPP+ (50 μM) by HEK-Co
and HEK-OCT1 cells. In both cases OCT1-mediated uptake (squares) of [3H]MPP+ was deter-
mined by subtracting uptake in HEK-Co cells from the uptake into HEK-OCT1 cells.
(TIF)
S2 Fig. Concentration-response curves of 1, 2 and 5 against Jurkat (A) and HT-29 (B) cells
after 96 hours of incubation. T/Ccorr values represent the net proliferation of the treated cells
referred to the vehicle treated control cells (set to 100%). The obtained data were used for the
calculation of IC50 values (mean values ± SEM of 2–3 independent experiments with 4 repli-
cates per concentration).
(TIF)
S3 Fig. Chemosensitivity of HEL92.1.7 cells against compounds 1 and 3–7. Antiprolifera-
tive/cytotoxic effects correspond to the left y-axes. The growth curves of untreated cells (open
circles) correspond to the right y-axes. Mean values ± SEM of 2–3 independent assays with 8
replicates per concentration and time point.
(TIF)
S4 Fig. Chemosensitivity of Jurkat cells against compounds 1 and 3–7. Antiproliferative/
cytotocix effects correspond to the left y-axes. The growth curves of untreated cells (open cir-
cles) correspond to the right y-axes. Mean values ± SEM of 2–3 independent assays with 8 rep-
licates per concentration and time point.
(TIF)
S5 Fig. Chemosensitivity of U-937 cells against compounds 1 and 3–7. Antiproliferative/
cytotoxic effects correspond to the left y-axes. The growth curves of untreated cells (open cir-
cles) correspond to the right y-axes. Mean values ± SEM of 2–3 independent assays with 8 rep-
licates per concentration and time point.
(TIF)
S6 Fig. Chemosensitivity of MG-63 cells against compounds 1 and 3–7. Antiproliferative
and cytocidal effects correspond to the left y-axes. The growth curves of untreated cells (open
circles) correspond to the right y-axes. Mean values ± SEM of 2–3 independent assays with 8
replicates per concentration and time point.
(TIF)
S7 Fig. Chemosensitivity of SK-ES-1 cells against compounds 1 and 3–7. Antiproliferative/
cytotoxic effects correspond to the left y-axes. The growth curves of untreated cells (open cir-
cles) correspond to the right y-axes. Mean values ± SEM of 2–3 independent assays with 8 rep-
licates per concentration and time point.
(TIF)
Cytotoxicity of Bendamustine Esters
PLOS ONE | DOI:10.1371/journal.pone.0133743 July 21, 2015 16 / 21
S8 Fig. Chemosensitivity of Capan-1 cells against compounds 1 and 3–7. Antiproliferative
and cytocidal effects correspond to the left y-axes. The growth curves of untreated cells (open
circles) correspond to the right y-axes. Mean values ± SEM of 2–3 independent assays with 8
replicates per concentration and time point.
(TIF)
S9 Fig. Chemosensitivity of LNCaP cells against compounds 1 and 3–7. Antiproliferative/
cytotoxic effects correspond to the left y-axes. The growth curves of untreated cells (open cir-
cles) correspond to the right y-axes. Mean values ± SEM of 2–3 independent assays with 8 rep-
licates per concentration and time point.
(TIF)
S10 Fig. Chemosensitivity of NCI-H460 cells against compounds 1 and 3–7. Antiprolifera-
tive and cytocidal effects correspond to the left y-axes. The growth curves of untreated cells
(open circles) correspond to the right y-axes. Mean values ± SEM of 2–3 independent assays
with 8 replicates per concentration and time point.
(TIF)
S11 Fig. Chemosensitivity of HT-29 cells against compounds 1 and 3–7. Antiproliferative
and cytocidal effects correspond to the left y-axes. The growth curves of untreated cells (open
circles) correspond to the right y-axes. Mean values ± SEM of 2–3 independent assays with 8
replicates per concentration and time point.
(TIF)
S12 Fig. Chemosensitivity of SK-MEL-3 cells against compounds 1 and 3–7. Antiprolifera-
tive and cytocidal effects correspond to the left y-axes. The growth curves of untreated cells
(open circles) correspond to the right y-axes. Mean values ± SEM of 2–3 independent assays
with 8 replicates per concentration and time point.
(TIF)
S13 Fig. Chemosensitivity of NCI-H460 (A), HT-29 (B) and HaCaT (C) cells against com-
pound 2. Antiproliferative and cytocidal effects correspond to the left y-axes. The growth
curves of untreated cells (open circles) correspond to the right y-axes. Mean values ± SEM of
2–3 independent assays with 8 replicates per concentration and time point.
(TIF)
S14 Fig. Flow cytometric analysis of Jurkat cells. Cells were treated with 10 μM 1, 2, 4 and 5
after different periods of incubation (6, 24, 48 hours) by annexin V-FITC (x-axis) and propi-
dium iodide (y-axis) staining. Samples of untreated cells were collected at the same time points
and served as control (Ctrl). The indicated percentages are related to the total number of col-
lected single cells. The different test compounds are arranged horizontally.
(TIF)
S15 Fig. Stability of compounds 1 and 4 in the presence of NCI-H460 cells. Representative
chromatograms, indicating the stability of compounds 1 and 4 in the presence of NCI-H460
cells (IS = internal standard, umbelliferone). Samples were measured immediately before the
incubation (t = 0 minutes) and after 10 minutes of incubation at 25°C (t = 10 minutes). The
kinetics of the hydrolysis of the N-Lost group, yielding 1a or 4a, is the same in case of benda-
mustine (1) and the morpholinoethyl ester 4, respectively. Other decomposition products were
not detected. The same holds for compounds 2 and 5 upon incubation with cells under the
same conditions (data not shown).
(TIF)
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S16 Fig. Semi-quantitative analysis of the SLC22A1 and SLC22A3mRNA expression in dif-
ferent cancer cell types. SLC22A1, SLC22A3 and β-actinmRNA levels were determined using
the semiquantitative LightCycler system and the mRNA expression values of SLC22A1 and
SLC22A3 are given in percentage of the β-actin amplification.
(TIF)
S1 Methods.
(PDF)
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